<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362960</url>
  </required_header>
  <id_info>
    <org_study_id>SE-866/29</org_study_id>
    <nct_id>NCT00362960</nct_id>
  </id_info>
  <brief_title>Olmesartan Medoxomil and Diabetic Nephropathy</brief_title>
  <official_title>Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sankyo Pharma Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function
      and inflammatory markers in patients with diabetic nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of olmesartan medoxomil doses compared to losartan in</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>patients with type 2 diabetes and nephropathy in terms of the change in</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>proteinuria (total urinary protein excretion) from baseline.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment with olmesartan medoxomil dosages compared to</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>losartan in patients with type 2 diabetes and nephropathy in terms of</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine clearance (CLCR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the protein pattern (nephelometry)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers (circulating serum markers).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety and tolerability of all treatments.</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathy</condition>
  <condition>Proteinuria</condition>
  <condition>Renal Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female European out-patients

          -  Greater than or equal to 30 years of age

          -  Type 2 diabetes first diagnosed at greater than or equal to 30 years of age

          -  Urinary protein excretion between 200-4000 mg/day exclusive

          -  Mean sitting dBP less than or equal to 110 mgHg

          -  Medically justifiable to withdraw antihypertensive treatment due to poor tolerability
             or inefficacy of previous treatment, or verification that treatment is still necessary

        Exclusion Criteria:

          -  Females pregnant, nursing or planning to become pregnant or were of childbearing
             potential and not using acceptable methods of contraception

          -  Secondary forms of hypertension other than diabetic nephropathy, malignant
             hypertension or patients with sitting dBP exceeding 110 mmHg or sitting sBP exceeding
             200 mmHg

          -  ECG evidence of 2nd or 3rd degree AV-block, atrial fibrillation, cardiac arrhythmia
             (requiring therapy) or bradycardia

          -  Presence of significant cardiovascular disease

          -  Significant cerebrovascular disease, gastrointestinal, haematological or hepatic
             disease or myocardial infarction in last 12 months or a previous history of any
             serious underlying disease

          -  Concurrent renal disease, nephrectomy and/or renal transplant, serum creatinine level
             greater than or equal to 2.0 mg/dL or creatinine clearance CLCR less than or equal to
             50 mL/min

          -  Clinically significant lab abnormalities (ASAT/SGOT, ALAT/SGPT and Î³-GT )

          -  Serum potassium level &lt; 2.5 mmol/L or &gt; 5.5 mmol/L

          -  Treatment of concurrent indications with drugs or medication which could have
             influenced BP

          -  History of hypersensitivity, lack of response or contraindication to Ang
             II-antagonists, HCTZ or atenolol, or hypersensitivity to related drugs (cross-allergy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H Haller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Frydlant v Cechach</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifenstein-Beilstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwijndrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pruszkow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Watlack</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolomin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sahy</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>October 6, 2006</last_update_submitted>
  <last_update_submitted_qc>October 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2006</last_update_posted>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Inflammatory Markers</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Renal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

